A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer
18 Years
75 Years
Female
Breast Cancer
Trial Information
A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer
Eligible breast cancer patients with mastectomy and axillary dissection are randomized into
2 groups:conventional fractionation radiotherapy of 50 Gy in 25 fractions within 5 weeks to
ipsilateral chest wall and supraclavicular nodal region,and hypofractionation radiotherapy
of 43.5Gy in 15 fractions within 3 weeks to the same region.
During and after radiotherapy, the patients are followed and the efficacy and toxicities of
radiotherapy are evaluated.
Inclusion Criteria:
- Ipsilateral histologically confirmed invasive breast cancer
- Undergone total mastectomy and axillary dissection
- T3-4,or axillary lymph nodes positive
- Fit for chemotherapy(if indicated),endocrine therapy(if indicated)and postoperative
irradiation
- Written,informed consent
Exclusion Criteria:
- Patients who undergone previous irradiation to the ipsilateral chest wall and
supraclavicular region
- Previous or concurrent malignant other than non-melanomatous skin cancer
- Unable or unwilling to give informed consent
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
locoregional control rate
Outcome Time Frame:
5 years
Safety Issue:
No
Principal Investigator
shu-lian wang, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Cancer Hospital, Chinese Academy of Medical Sciences
Authority:
China: Ethics Committee
Study ID:
LC2008A06
NCT ID:
NCT00793962
Start Date:
June 2008
Completion Date:
October 2015
Related Keywords:
- Breast Cancer
- breast cancer
- mastectomy
- radiotherapy
- fractionation
- Breast Neoplasms
Name | Location |
|---|
